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Herein, by using a mouse cancer cell line grown in an immunocompetent syngeneic NFκB-luc2 reporter mouse model and a fluorescent dye to track EVs [35] , we took advantage of in vivo and ex vivo imaging technologies to evaluate, at the same time, the biodistribution and the effects of EVformulations carrying OVs and/or paclitaxel (PTX) on the immune system. We found that EVs enhanced the systemic delivery of anticancer agents resulting in an improved tumor-selective delivery, peritumoral immune-response associated with the targeted delivery of the virus, enhanced immunogenicity and infiltration of CD4+ and CD8+ T-cells.
MATERIALS AND METHODS

Cell culture
LL/2 mouse lung cancer cell line was purchased from the American Type Culture Collection (ATCC, USA). The cells were cultured at 37 °C and 5 % CO 2 in Dulbecco's modified eagle medium (DMEM, Lonza, Switzerland) supplemented with 10 % fetal bovine serum (FBS, Gibco Laboratories, USA), 1 % of 100 u/mL penicillin/streptomycin (Gibco Laboratories) and 1% L-glutamine (Gibco Laboratories).
Oncolytic virus
The construction and characterization of Ad5D24-CpG has been described previously [50] by recombining a CpG-rich shuttle plasmid (pTHSN-CpG1) with a plasmid containing the 24 adenovirus backbone. Viral stocks were expanded in human lung cancer cell line A549 and purified on cesium chloride gradients. The viral particle concentration was determined b y OD 260 -reading and standard TCID 50 (tissue culture infectious dose 50) assay was performed to determine infectious particle titer. Virus was characterized by PCR and restriction enzyme.
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EVs were isolated from the conditioned medium using differential centrifugation steps. First the conditioned medium was centrifuged at 500 x g in 4°C for 10 minutes to pellet cells (Allegra X-15R
Centrifuge, Beckman Coulter). Then, the supernatant was collected and ultra-centrifuged for 2 h at 100 000 x g in 4°C, using Optima L-80 XP ultra-centrifuge (Beckman Coulter) with rotor SW32Ti
(Beckman Coulter). The supernatant was aspirated and EV-containing pellets re-suspended in PBS (Lonza) 100 μL and stored at -80 °C.
PTX-loaded EVs were prepared as previously described [37, 39] by incubating 1 × 10 8 -5 × 10 9 EVs in 1 mL of 5 μM PTX-PBS solution for in vitro samples and 10 μM PTX-PBS solution for in vivo samples, for 1 h at 22 °C. Then, the samples were centrifuged at 170000 ×g for 2 h to pellet the EVs.
The supernatant containing unbound PTX was removed, and the EV-pellet was washed, suspended it in DPBS and pelletted it again at 170000 ×g.
EVs were loaded with DiD lipohilic dye (EV-DiD) and prepared by incubating 1x10 8 -5 x10 9 EVs for 1 hour at RT with 5 μL of DiD (Biotium) per mL of EV suspension in PBS. Next, the samples were centrifuged at 150 000 x g for 3 h to pellet the EVs. The supernatant containing unbound DiD was removed, and the EV-pellet was washed by suspending it in PBS and pelleting it again at 150 000 x g.
Production of EV-Virus formulations
EV-encapsulated virus (EV-Virus) were produced as previously described [39] , 2.6 x 10 6 of LL/2 cells were infected with 10 viral particles/cell of Ad5D24CpG and were cultured at 37 °C and 5 % CO 2 .. 48 h later when most of the cells were detached from the culture flask, the culture media were collected for EV-Virus isolation using differential centrifugation. First the conditioned medium was centrifuged at 500 x g and 4°C for 10 minutes, to separate the cells (Allegra X-15R Centrifuge, Beckman Coulter). Then, the supernatant containing EV-Virus was collected and ultra-centrifuged for 2 h at 100 000 x g and 4°C, using Optima L-80 XP ultra-centrifuge (Beckman Coulter) with rotor SW32Ti (Beckman Coulter). The supernatant was aspirated and pellets containing EV-Virus resuspended in PBS 100μL and stored at -80 °C. EV-Virus samples were incubated in 100 mM NaOH at room temperature for 20 minutes in order to inactivate any free not EV encapsulated virus present.
Free virus used as controls was always inactivated for each experiment performed as previously reported [51, 52] . Samples were subsequently neutralized by the addition of HCl 0.1 M.
To generate EV-DiD-Virus, the EV-Virus formulation was incubated for 1h at RT in 5 μL of DiD per mL of EV suspension in DPBS. Samples were then centrifuged at 150 000 x g for 3 h at RT, in order to pellet EV-DiD-Virus. The washing procedure was repeated using PBS as diluent. The final EVDiD-Virus pellet was re-suspended in 100 μL of PBS and stored at -80 °C until use.
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Size distribution analysis by nanoparticle tracking analysis (NTA)
Size distribution and concentration of EV, EV-PTX, EV-Virus and EV-Virus-PTX formulations were analyzed by NTA using Nanosight model LM14 (Nanosight) equipped with blue (404 nm, 70 mV) laser and sCMOS camera. The samples containing virus were incubated at +95 °C for 10 minutes in order to inactivate the viruses. NTA was performed for each sample by recording three 90 seconds videos, subsequently analyzed using NTA software 3.0 (Nanosight). The detection threshold was set to level 5 and camera level to 15.
Zeta potential analysis by electrophoretic light scattering
The zeta potential was measured using ZetaSizer Nano (Malvern, UK). All the samples were diluted in a volume of 800 μL of MilliQ H 2 O and injected with a 1 mL syringe in the capillary flow (DTS1070 folded capillary cell) for the measurement. An equilibration time of 120 seconds was set on the software to allow the samples to stabilize at 25°C inside the measurement chamber. Three parallel measurements were performed on each sample.
Cryo-EM
Cryo-EM images were acquired with a FEI Talos Arctica 200 kV FEG electron microscope equipped with a FEI Falcon 3EC direct electron detector and Volta Phase-plate. Prior to Cryo-EV imaging, samples were vitrified on a FEI Vitrobot IV apparatus, and processed as previously reported [53] .
MTS cell viability assay
LL/2 cells were seeded at a density of 1x10 4 
In vivo and ex vivo imaging
The in vivo bioluminescence imaging analysis was carried out at different time points, starting the 
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The in vivo fluorescence imaging was carried out 24 h post i.v. EV treatments using the same Imaging System (IVIS Lumina II) with suitable filters (Cy5.5) and following the manufacturer instructions for fluorescence background subtraction. Similarly, to the above-described procedure for bioluminescence imaging, the ex vivo imaging acquisition of fluorescence was performed on tissue explants over an exposition time of 1 second. The quantification was done with Living Image Software 3.2 (PerkinElmer).
Quantitative real-time PCR
qPCR for adenovirus E4 copy number was carried out according to the protocol previously described 
Immune cell infiltration analysis
Immune cell infiltration of tumors was analyzed using the flow cytometer BD LSR II (BD Biosciences) and FlowJo software (Tree Star, Ashland, OR, USA) at sacrifice (24h post-treatment).
Specific lymphocites were quantified using antibodies CD45+ (Abcam, ab210185), CD3+ (Abcam, 
Statistical analysis
Statistical significance was analyzed by using one-way ANOVA with Tukey's Multiple Comparison test and nonparametric Mann-Whitney test. All statistical analysis, calculations and tests were ACCEPTED MANUSCRIPT
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10 performed using GraphPad Prism 5 (GraphPad Software, San Diego, CA).
RESULTS
Production of LL/2-derived EVs formulations and their ability to induce immunogenic cell death
We previously demonstrated that human lung cancer cell-derived EVs could be useful vehicles for the systemic drug delivery of OVs and paclitaxel (PTX) to target and reduce tumor growth in nude mice with compromised immune system [39] . Since, OVs are able to trigger the host anti-tumor immunity actively contributing to their mechanism of action [56, 57] , in the current study, we aimed at evaluating the effects of EV formulations on the immune system; for testing these effects, we used a mouse lung cancer cell line (LL/2) to produce the EV-formulations (encapsulating PTX and OVs) and to generate a tumor model in immunocompetent syngeneic mice (C57Bl/6). In a first set of experiments, we assessed whether the encapsulation of PTX and OVs into the LL/2-derived EVs had influence on the particle size distribution by using NTA ( Figure 1AB ). After encapsulation, free viruses remaining in solution were chemically inactivated as previously reported [51, 52] Indeed, EVs and EV-Virus had a negative zeta-potential of approximately -40 mV, while the free virus had a zeta-potential of -20 mV ( Figure 1C ). The zeta-potential was also comparable in EVVirus-PTX and EV-PTX formulations, as PTX is a chargeless molecule ( Figure 1C ). Cryo-EM experiments showed that virus was incorporated inside the vesicles. The adenovirus virion has a viral structure of 90-100 nm in size packed inside the EV ( Figure 1D ). Although we rigorously standardized the procedure for the encapsulation of the virus into the EVs, the ratio between free and EV-encapsulated virus could not be systematically determined. The Cryo-EM images demonstrated that the free virus was less frequent compared to the encapsulated virus, but this was only a qualitative observation that for future clinical applications should be firmly determined. Nevertheless, the remaining free virus was routinely inactivated (please, see the procedure in the Material and Methods section) in the EV-Virus formulations before proceeding with the in vivo experiments.
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A C C E P T E D M A N U S C R I P T (Fig. 2D) ; the treatment with PTX slightly decreased viral replication although to a minimal extent (25%). These data suggested that all EV formulations, but not EVs alone, were able to counteract the growth of tumor cells and induce immunogenic cell death. we found levels comparable with those measured in samples used as negative controls, such as t he brain and serum; in contrast, as expected, a very high titer was detected in the tumor ( Figure 6A ). By changing the scale of fluorescence of three orders of magnitude, minor distribution could be detected also in other tissues mainly spleen, brain, kidneys, lungs and intestine, although these signals were lower than those detected in the tumor (Supplementary Figure 7) . The higher signal in spleen (among the lowers) is in agreement with previous reports with other nanoparticles showing a preferential uptake in the spleen; this phenomena might be less evident in our experiments because of the tumor tropism of EVs.
A C C E P T E D M A N U S C R I P T 
Peritumoral infiltration of TILs induced by oncolytic viruses is unaffected by EVs
Next, we analyzed whether the type of inflammatory response recruited by the OVs [62] , could be influenced by the delivery of the virus via EVs. To this aim, the immune cells infiltrating the resected tumors were analyzed by flow cytometry at sacrifice, 24h post-treatment; the amount of murine CD45+ (pan-leucocyte marker) was initially quantified ( Figure 6B ) and then the proportion of murine CD3+ T-cells among CD45+ leukocytes was calculated: the data indicated that there was a trend to increase of the CD3+ cell type in the Virus, EV-Virus and EV-Virus-PTX groups ( Figure   6C ). Similar data were obtained for the subpopulation of CD4+ and CD8+ T-cells displaying a nonsignificant increased infiltration in the same treatment groups ( Figure 6DE ). Therefore, we concluded that OVs alone or EV encapsulated with other drugs might enhance immunogenicity; although the significance of this observation has to be firmly established in future studies, we could conclude that the encapsulation of virus into EVs was not interfering with the observed immunogenic response. 
DISCUSSION
The use of EVs as delivery system of OVs [39, 63] or anti-neoplastic drugs [37, 64] is a promising therapeutic strategy for primary and metastatic cancers. Nevertheless, the EVs biodistribution profile [65] and the potential side-effects associated with the systemic administration of OVs encapsulated in EVs are still poorly characterized. We have previously developed a strategy to encapsulate in EVs anti-cancer agents, including OVs and PTX together, showing, for the first time, that these formulations can be administered systemically: we reported a selective cancer cell tropism along with inhibition of cancer cell growth in nude mice, thus exploiting their potential use of these novel therapeutic concept also for the treatment of metastatic cancers [39] . In the current study, by using an immunocompetent reporter mouse model (NFkB-luc2), we aimed at assessing the effects of the intravenous delivery of these EVs formulations on the systemic and tumor-associated inflammation.
In fact, although extensive studies have been conducted to demonstrate their potential as drug delivery vessels [34, 38, [66] [67] [68] [69] , still little is known about the possible immunogenic or potential toxic effects of EVs [70] . This is especially important given that some of the EV cargo may carry toxic
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A C C E P T E D M A N U S C R I P T 22 constituents or may instigate inflammatory responses [70] [71] [72] . Our in vivo imaging evidence on EVs biodistribution clearly show a targeted delivery of the particles selectively to the tumor tissues: we found that the systemic effects of PTX resulting in a diffuse inflammatory reaction, were efficiently reduced by encapsulating the drug inside EVs ( Figure 4AF ). This is a promising result showing that the potential toxic and inflammatory effects of PTX on the whole body can be prevented by the ability of the nanoparticles to specifically target the tumor tissue. In addition, it has been previously reported that EVs may release mediators of the immune response, such as interleukin (IL)-1β [73] [74] [75] , IL-18 [76] , IL-8 [77] , lipid mediators [78, 79] , matrix metalloproteinases [80] and miRNAs such as let-7, miRNA-21, and miR-29a [81, 82] , nevertheless, our in vivo imaging data clearly indicate that no systemic reaction could be detected other than the tumor associated inflammation.
It is well-known that tumor-associated inflammation may have positive or negative effects depending on the type of the produced immune response [83] : while cytotoxic response is essential for tumor cell removal from the body [84] , the response associated with tissue repair may promote invasion and angiogenesis through the secretion of specific growth factors and cytokines [85, 86] . The ability of Despite these potential advantages in using EVs as drug delivery tools, there are still some challenges to overcome for its clinical application. Currently there are no universal protocols for EV production, as carriers for drug delivery, thus a standardized protocol should be developed in the near future [88] .
Indeed, the low production yield of EVs together with their short half-life, after i.v. administration, is a big hurdle that need to be beaten [66, [88] [89] [90] before their application for clinical purposes. It has A C C E P T E D M A N U S C R I P T 23 been reported that some cancer cell-derived EVs have a nano-filamentous network, which facilitates interaction with the cell membrane and increases the EV-uptake [67] . These characteristics could possibly be considered for improvements in the design of efficient EV-based drug carriers to be used in cancer therapy [91] . Future studies should take advantage of the EVs pseudo-typing to improve specificity and to drive their tropism towards specific cancers. 
CONCLUSION
In this study, we supported EVs as a tool for systemic delivery of anticancer agents alone or in a combination therapy. We demonstrated the ability of EVs to selectively deliver anti-neoplastic agents to the tumor tissue, thus, potentially reducing the systemic effect of chemotherapy. Moreover, we
showed that encapsulation into EVs does not change the ability of OVs to stimulate a tumorassociated inflammatory response in terms of NFκB stimulation, enhanced immunogenicity and infiltration of CD3+, CD4+ and CD8+ T-cells. Altogether, our experiments strongly support the systemic administration of anticancer agent combinations encapsulated into EVs as a novel, safe and efficacious therapeutic strategy aimed at treating primary and metastatic cancers.
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